These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 10372838)

  • 61. Calcium acetate versus calcium carbonate and erythropoietin dosages in haemodialysis patients.
    Janssen MJ; van der Kuy A; ter Wee PM; van Boven WP
    Nephrol Dial Transplant; 1995 Dec; 10(12):2321-4. PubMed ID: 8808233
    [No Abstract]   [Full Text] [Related]  

  • 62. The prevention of secondary hyperparathyroidism.
    Cunningham J
    Curr Opin Nephrol Hypertens; 1993 Jul; 2(4):552-7. PubMed ID: 7859017
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Insulin secretion in uremia: effect of parathyroid hormone and vitamin D metabolites.
    Mak RH
    Kidney Int Suppl; 1989 Nov; 27():S227-30. PubMed ID: 2699996
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Treatment of secondary hyperparathyroidism with vitamin D derivatives and calcimimetics before and after start of dialysis.
    Drüeke TB
    Nephrol Dial Transplant; 2002; 17 Suppl 11():20-2. PubMed ID: 12386252
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Calcium mass balance and behavior of intact immunoreactive parathyroid hormone in acetate-free biofiltration: acute and one-year evaluation.
    de Vincenzi A; Bellazzi R; Santagostino M; Romanini D; Nai M; Gazo A; Bacchella L; Gini A
    Blood Purif; 1994; 12(2):85-94. PubMed ID: 7826579
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Vitamin D analogs: new therapeutic agents for secondary hyperparathyroidism.
    Brown AJ; Coyne DW
    Treat Endocrinol; 2002; 1(5):313-27. PubMed ID: 15832485
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Recent progress in management of secondary hyperparathyroidism of chronic renal failure.
    Akizawa T; Fukagawa M; Koshikawa S; Kurokawa K
    Curr Opin Nephrol Hypertens; 1993 Jul; 2(4):558-65. PubMed ID: 7859018
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Secondary hyperparathyroidism.
    McKenna MJ; Freaney R
    Ann Clin Biochem; 1993 Sep; 30 ( Pt 5)():504-6. PubMed ID: 8250510
    [No Abstract]   [Full Text] [Related]  

  • 69. Prevention of renal osteodystrophy.
    Baker LR
    Miner Electrolyte Metab; 1991; 17(4):240-9. PubMed ID: 1813786
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Molecular pathogenesis of secondary hyperparathyroidism in renal failure: basic and clinical aspects.
    Fukagawa M; Iwasaki Y
    Nephrol Dial Transplant; 1999; 14 Suppl 1():61-2. PubMed ID: 10048454
    [No Abstract]   [Full Text] [Related]  

  • 71. Management of disturbed calcium metabolism in uraemic patients: 2. Indications for parathyroidectomy.
    Schömig M; Ritz E
    Nephrol Dial Transplant; 2000; 15 Suppl 5():25-9. PubMed ID: 11073271
    [No Abstract]   [Full Text] [Related]  

  • 72. Reversal of hyperparathyroidism in severe uremics following very low-protein and low-phosphorus diet.
    Barsotti G; Morelli E; Guiducci A; Ciardella F; Giannoni A; Lupetti S; Giovannetti S
    Nephron; 1982; 30(4):310-3. PubMed ID: 7110461
    [No Abstract]   [Full Text] [Related]  

  • 73. Primary and secondary uraemic hyperparathyroidism: from initial clinical observations to recent findings.
    Drüeke TB
    Nephrol Dial Transplant; 1998 Jun; 13(6):1384-7. PubMed ID: 9641165
    [No Abstract]   [Full Text] [Related]  

  • 74. Effects of 1,25-dihydroxy vitamin D3 in patients with early renal failure.
    Lam M; Llach F
    Adv Exp Med Biol; 1982; 151():361-73. PubMed ID: 6897482
    [No Abstract]   [Full Text] [Related]  

  • 75. Is Fibroblast Growth Factor-23 a novel marker for phosphate burden in chronic kidney disease with prognostic implications?
    Bielesz B
    Wien Klin Wochenschr; 2010 Apr; 122(7-8):194-7. PubMed ID: 20503017
    [No Abstract]   [Full Text] [Related]  

  • 76. [Treatment of severe uremic hyperparathyroidism using a method for percutaneous injection of the parathyroid glands with ethanol].
    Niemczyk S; Elwerowski M; Matuszkiewicz-Rowińska J; Sitkowska-Kurzec Z; Sokalski A; Dziecioł-Jastrzebska M; Gomółka M; Kulicki P; Karolak B; Przedlacki J
    Pol Arch Med Wewn; 1999 Feb; 101(2):139-43. PubMed ID: 10723228
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Development of hypercalcemic hyperparathyroidism after long-term phosphate supplementation in hypophosphatemic osteomalacia. Report of two cases.
    Firth RG; Grant CS; Riggs BL
    Am J Med; 1985 Apr; 78(4):669-73. PubMed ID: 2984933
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Interaction between active metabolites of vitamin D3 and blood aluminum in chronic uremic patients on dialysis].
    Panico F; Salvati A; Scoppa F; Testa GF; Capobianco A; Pacia S; Lauriello F; Aquino A; Tedesco V; Taccone W
    Minerva Urol Nefrol; 1993 Jun; 45(2):47-8. PubMed ID: 8235931
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Cell biology of parathyroid hyperplasia in uremia.
    Fukagawa M
    Am J Med Sci; 1999 Jun; 317(6):377-82. PubMed ID: 10372837
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Are parathyroidectomies still appropriate in chronic dialysis patients?
    Cunningham J
    Semin Dial; 2000; 13(5):275-8. PubMed ID: 11014687
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.